023910 — DaehanPharmaceutical Income Statement
0.000.00%
Last trade - 00:00
- KR₩168bn
- KR₩64bn
- KR₩196bn
- 99
- 87
- 68
- 98
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 168,762 | 166,080 | 171,463 | 184,268 | 195,911 |
Cost of Revenue | |||||
Gross Profit | 59,495 | 56,536 | 56,039 | 60,242 | 65,922 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 135,123 | 136,147 | 142,528 | 151,399 | 160,197 |
Operating Profit | 33,639 | 29,933 | 28,935 | 32,868 | 35,714 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 37,131 | 22,532 | 30,433 | 33,451 | 36,734 |
Provision for Income Taxes | |||||
Net Income After Taxes | 28,167 | 17,381 | 22,670 | 24,961 | 28,426 |
Net Income Before Extraordinary Items | |||||
Net Income | 28,167 | 17,381 | 22,670 | 24,961 | 28,426 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 28,167 | 17,381 | 22,670 | 24,961 | 28,426 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 4,691 | 3,882 | 3,790 | 4,184 | 4,842 |
Dividends per Share |